Approximately 90% of people with type 2 diabetes (T2D) have overweight or obesity. Thus, weight management is a highly relevant clinical issue in this patient population. However, studies of obesity treatment in people with T2D consistently show that people with T2D lose less weight than people who do not have diabetes. There are many reasons why weight loss can be more difficult to achieve for people with diabetes.

Some medications can cause weight gain, as can cessation of hyperglycemia-associated glucosuria with acquisition of glucose control. Complications of DM can limit physical activity. Hypoglycemia can lead to weight gain, not only because treatment of hypoglycemia requires the ingestion of carbohydrates, but also because some patients may consume more calories than necessary to prevent hypoglycemia (‘defensive snacking’) or engage in a compensatory increase in food consumption due to fear of hypoglycemia. The stress and burden of diabetes can also lead to emotional eating. Furthermore, insulin resistance is often cited as making weight loss more challenging, though the mechanisms at play here are poorly understood.

**Figure 1:** Reasons weight loss can be more difficult to achieve in people with diabetes$^{1,2,3,4}$

Dr. Sue Pedersen is a Specialist in Endocrinology & Metabolism and a certified American Board of Obesity Medicine (ABOM) diplomate. She completed her training as an endocrinologist at the University of Calgary in 2005 and has a busy endocrinology practice at the C-ENDO Diabetes & Endocrinology Clinic in Calgary. She is the lead author on the pharmacotherapy chapter of the 2020 and 2022 Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the 2018 Diabetes Canada guidelines as a co-author of the Weight Management chapter. She is a principal investigator for several studies of diabetes and obesity pharmacotherapy, and a co-author of many of the resultant publications. She has a public information website for healthcare providers and patients about obesity and diabetes (www.drsue.ca).
Weight loss is associated with improvement in various comorbidities related to obesity, including glycemia. Among individuals with prediabetes, one kilogram of weight loss is associated with a 16% relative risk reduction in the development of T2D. An approximate 15% weight loss from baseline with lifestyle intervention can lead to remission of T2D, especially when the duration of diabetes is short. While these data for lifestyle interventions are encouraging, the vast majority of people who lose weight with the help of lifestyle intervention are not able to maintain the weight loss over the long term due to natural biology which drives weight regain through increase in ghrelin, reduction in satiety hormones, and a reduction in resting energy expenditure. Another challenge is that these interventions may be difficult to implement in real-world clinical practice.

**So what do the Canadian obesity guidelines recommend for people with T2D?**

The three pillars of obesity management that support medical nutrition therapy and physical activity are psychological support, pharmacotherapy, and/or bariatric surgery (Figure 2).

The Canadian obesity guidelines recommend choosing therapy from these pillars as appropriate for each patient. Lifestyle approaches, which include medical nutrition therapy and physical activity, are not sufficient interventions in and of themselves; rather, the pillars of treatment facilitate adherence to healthier lifestyles.

---

**Figure 2:** Three pillars of obesity management that support medical nutrition therapy & physical activity.

**Figure 3:** Effects of glucose-lowering agents on body weight: network meta-analysis of 394 trials. Adapted from Kakotrichi P et al. 13
Medical Nutrition Therapy

There are numerous nutritional approaches that can improve glycemia with or without a small amount of weight loss. These approaches include following the Mediterranean dietary pattern, a vegetarian diet, low glycemic index, a DASH (Dietary Approaches to Stop Hypertension) diet, and the inclusion of pulses (e.g., beans), vegetables, and nuts as part of one’s routine nutritional consumption. It is recommended that nutrition plans should be personalized to ensure that they meet individual values and preferences and are safe, effective, nutritionally adequate, culturally acceptable, and affordable for long-term adherence. It is recommended to consider intensive lifestyle interventions that target a 7–15% weight loss to increase the likelihood of remission of T2D.

Physical Activity

Meta-analyses have consistently shown improvements in Hemoglobin A1c (A1c) following structured or supervised aerobic and/or resistance exercise training in people with T2D, even in the absence of weight loss. Numerous studies have demonstrated that exercise with or without dietary interventions can reduce the risk of type 2 diabetes by 38–58% among people with prediabetes.

Pharmacotherapy

According to the Obesity Canada guidelines, when choosing the most appropriate medications for glycemic control, the effect of glucose-lowering pharmacotherapy on weight should be considered. GLP-1 receptor agonists and sodium/glucose cotransporter 2 (SGLT2) inhibitors are associated with weight loss in addition to improving glycemic control. Other agents such as metformin, DPP-4 inhibitors, and acarbose are typically weight-neutral. Insulin, insulin secretagogues, and thiazolidinediones (TZDs) are associated with weight gain. As GLP-1 receptor agonists and SGLT2 inhibitors address the coincident goals of weight loss, glycemic control, and cardiorenal protection, they should be prioritized for the treatment of T2D.

When used in conjunction with health behaviour changes, obesity pharmacotherapy can facilitate weight management, improve glycemic control, and reduce the need for other glucose-lowering medication for people with T2D and a BMI ≥ 27 kg/m^2^. Figure 4 illustrates the placebo-subtracted weight loss efficacy of approved obesity pharmacotherapies in people with T2D. This depiction illustrates an indirect treatment comparison and is not from head-to-head trials. Readers should note that patients differ in terms of background glucose lowering medication, the duration of their T2D, and other important demographic and disease-related factors.

Orlistat is a pancreatic lipase inhibitor, inhibiting the absorption of ingested fat and thereby creating a caloric deficit. A meta-analysis of patients with T2D and obesity found that patients treated for 6 or 12 months with 120 mg orlistat t.i.d. had significantly greater reduction in A1c compared with placebo (0.74% vs. 0.31%, respectively). The average weight loss in the orlistat group was 3.8kg compared to a loss of 1.4kg for patients in the placebo arm. The primary reason for improvement in glycemic control with orlistat is weight loss.

Liraglutide is a GLP-1 receptor agonist that acts centrally to improve satiation and satiety and reduce
hunger, with a transient effect to decrease gastric emptying.\textsuperscript{19,20} Liraglutide is approved for T2D at a dose of 1.2 mg or 1.8 mg daily, with near-maximal efficacy for A1c lowering at the 1.8 mg dose. It is approved for long-term obesity management at a dose of 3.0 mg daily for people with or without T2D. In people with obesity and T2DM managed with 0-3 oral agents, the SCALE randomized clinical trial found that in conjunction with health behaviour change, liraglutide 3.0 mg reduced weight by -6.0%, vs -4.7% with liraglutide 1.8 mg and -2.0% with placebo at 56 weeks.\textsuperscript{21} A1c was reduced by 1.3% in the liraglutide 3.0 mg group, 1.1% in the liraglutide 1.8 mg group, and 0.3% in those receiving placebo.

Naltrexone/bupropion is approved for obesity management as a combination tablet, which works by inducing satiety centrally and reducing cravings.\textsuperscript{22} Used along with health behaviour changes in adults with a BMI of 27–45 kg/m\textsuperscript{2} and T2D managed with oral agents or diet, naltrexone/bupropion-treated patients achieved a 5% weight reduction from baseline, compared with 1.8% with placebo, and achieved a 0.5% greater reduction in HbA1c vs placebo. The change in A1c was correlated with the change in body weight.

Semaglutide is a GLP-1 receptor agonist that acts centrally to improve satiation and satiety, reduce hunger, and reduce cravings.\textsuperscript{23} Semaglutide is approved for treatment of T2D at a dose of 0.5 mg, 1.0 mg, or 2.0 mg weekly, with near-maximal therapeutic efficacy for A1c lowering at the 1.0 mg dose. Semaglutide is approved in Canada for long-term obesity management at a dose of 2.4 mg weekly, in people with or without T2D. Among people with overweight or obesity and who have T2D managed with oral agents or health behaviours alone, semaglutide 2.4mg with health behaviour modification resulted in a superior weight loss of 9.6% at 68 weeks, compared to a loss of 7.0% with semaglutide 1.0 mg and 3.4% with placebo. Reduction in A1c was 1.6% with semaglutide 2.4 mg, 1.5% with semaglutide 1.0 mg, and 0.4% with placebo.

**Bariatric Surgery**

Bariatric surgery can be considered for people with BMI \( \geq 40 \text{ kg/m}^2 \) or BMI \( \geq 35 \text{ kg/m}^2 \) with T2D, to induce control and remission of T2D in combination with best medical management, over best medical management alone.\textsuperscript{24} Bariatric surgery should also be considered in patients with poorly controlled T2D and Class I obesity (BMI between 30 and 35 kg/m\textsuperscript{2})\textsuperscript{10} despite optimal medical management. Remission rates of diabetes at three years have been reported at 79% and 95% in Roux-en-Y gastric bypass and duodenal switch groups, respectively, compared to no response with medical intervention alone. Long-term outcome data from a randomized controlled trial found that 29% of patients who underwent Roux-en-Y gastric bypass and 23% who underwent sleeve gastrectomy maintained A1c levels of 6.0% or lower at 5 years, with or without the use of diabetes medications, compared to 5% of patients who underwent intensive medical therapy alone.\textsuperscript{25} Predictors of diabetes remission include higher preoperative serum C-peptide, younger age, shorter duration of diabetes, and lack of need of insulin therapy preoperatively.\textsuperscript{26} In people who experience diabetes remission, it is important that routine screening for diabetes continues lifelong, as recurrence of diabetes is common.

**Treating obesity earlier disrupts the natural history of T2D**

Weight gain, central adiposity, and insulin resistance, which ultimately lead to hyperglycemia, are typically present decades before a diagnosis of T2D. As shown in Figure 5, treatment in the early years of obesity provides the opportunity to prevent comorbidities related to excess adiposity. At the stage where metabolic syndrome has developed, treatment of obesity is targeted towards resolution of metabolic syndrome and prevention of prediabetes. During the prediabetes stage, potential outcomes of obesity management include remission of prediabetes and prevention of T2D, whereas if the same intervention is started after the onset of T2D, goals of treatment center on glycemic control or perhaps T2D remission. Once diabetes-related complications have developed, the focus is on treating or preventing progression of
those complications, in addition to
glycemic control.
While there are important
benefits to treating obesity across
the continuum, by treating obesity
earlier, we have the potential
to disrupt the natural history of
T2D. As such, a focus on weight
management must start as early
as possible in the continuum of
metabolic disease.
As most patients with T2D
will benefit from having a primary
weight-centric approach to
diabetes management, the 2022
ADA/EASD guidelines have been
updated to prioritize weight
management alongside glycemic
control and cardiorenal protection
in their diabetes pharmacotherapy
algorithm22—an important addition
to the treatment paradigm!

Clinical Pearls

- When any weight management
treatment modality is initiated
in a person with T2D, it is
important to consider any
needed reduction in insulin or
secretagogues for avoidance of
hypoglycemia.
- As weight decreases, reduction
in other medications (eg.
hypertension medications,
thyroid hormone treatment
for hypothyroidism) may be
required, and these parameters
should be monitored.
- For any patient who
experiences remission of
T2D or prediabetes with
any treatment modality, it is
essential that glycemic control
is re-evaluated regularly to
screen for recurrence.

Financial Disclosures

Honoraria: Abbott, AstraZeneca,
Bausch, Bayer, Boehringer, Dexcom,
HLS, Janssen, Lilly, Novo Nordisk, Pfizer,
Prometic, Sanofi
Advisory Boards/Speakers’ Bureau:
Abbott, AstraZeneca, Bausch, Bayer,
Boehringer, Dexcom, HLS, Janssen, Lilly,
Novo Nordisk, Pfizer, Prometic, Sanofi

References

1. Russell-Jones D, Khan R. Insulin-asso-
ciated weight gain in diabetes: causes,
effects and coping strategies. Diabe-
doi:10.1111/j.1463-1326.2006.00686.x
2. Van Gaal L, Scheen A. Weight manage-
ment in type 2 diabetes: current and
emerging approaches to treatment.
doi:10.2337/dc14-1630
3. Pi-Sunyer FX. Weight loss in type
28(6):1526-7. doi:10.2337/di-
acare.28.6.1526
4. Krenke J, Tan T, Bloom S. Treat-
ing the obese diabetic. Expert Rev
doi:10.1586/ercp.13.5
5. Diabetes Prevention Program Research
Group. 10-year follow-up of diabetes
incidence and weight loss in the Dia-
abetes Prevention Program Outcomes
doi:10.1016/S0140-6736(09)61457-4
6. Lean MEJ, Leslie WS, Barnes AC,
Brosnahan N, Thom G, McCom-
bie L, et al. Primary care-led weight
management for remission of type
2 diabetes (DiRECT): an open-la-
bel, cluster-randomised trial. Lancet.
2018;391(10120):541-51. doi:10.1016/
S0140-6736(17)33102-1
7. Lau DCW, Wharton S. Canadian adult
obesity clinical practice guidelines:
the science of obesity. Obesity Can-
da. 2020 Aug 4 [updated 2021 Mar
29; accessed 2022 Oct 30]. https://
obesitycanada.ca/guidelines/science.
Obesity in adults: a clinical practice
guideline. CMAJ. 2020;192(31):E875-
91. Appendix 2, 2020 clinical practice
guidelines: 5As framework for obesity
cmaj.191707
C, Sievenpiper J. Canadian adult obe-
sity clinical practice guidelines: med-
ical nutrition therapy in obesity
management. Obesity Canada. 2022 Oct
21 [accessed 2022 Oct 30]. https://
obesitycanada.ca/guidelines/nutrition.
10. Umpierre D, Ribeiro PAB, Kramer
CK, et al. Physical activity advice
only or structured exercise training
and association with HbA1c levels
in type 2 diabetes: a systematic
review and meta-analysis. JAMA.
jama.2011.576
11. Boulé NG, Prud’homme D. Canadian
adult obesity clinical practice guide-
lines: physical activity in obesity
management. Obesity Canada. 2020 Aug
4 [updated 2021 Mar 29; accessed
ca/guidelines/physicalactivity.
12. Pedersen SD, Manjoo P, Wharton S.
Canadian adult obesity clinical prac-
tice guidelines: pharmacotherapy
for obesity management. Obesity Can-
30]. https://obesitycanada.ca/guide-
lines/pharmacotherapy.
13. Kakotrichi P, Karagianniss T, Avgerinos
I, Mantsiou C, Tousinas G, Manol-
opoulos A, et al. Comparative effects
of medications for type 2 diabetes
on body weight: a systematic review
and network meta-analysis of 394 tri-
56th Annual Meeting of the European
Association for the Study of Diabetes;
org/media-centre/#resources/com-
parative-effects-of-medications-for-
type-2-diabetes-on-body-weight-a-
systematic-review-and-network-ma-
ta-analysis-of-394-trials-29a3e5d5-
8a31-427b-b975-5a943b429159.
of orlistat in combination with a
weight management programme in
obese patients with Type 2 diabe-
tes treated with metformin. Diabet
j.1464-5491.2004.01474.x
15. Hollander P, Gupta AK, Plodkows-
ki R, Greenway F, Bays H, Burns C,
Klassen P, Fujioka K; COR-Diabetes
Study Group. Effects of naltrexone
sustained-release/bupropion sus-
tained-release combination therapy
in obese patients with Type 2 diabe-
doi:10.2337/dc13-0234
16. Garvey WT, Birkenfeld AL, Dicker
D, Mingrone G, Pedersen SD, Satyl-
ganova A, et al. Efficacy and safety of
How to apply the Canadian Obesity Clinical Practice Guidelines
liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085-93. doi:10.2337/dc19-1745


